Mastodon

Gelplastan (Powder) Instructions for Use

Marketing Authorization Holder

Tanais R&D, LLC (Russia)

Manufactured By

Shchelkovsky Biocombinat, FSE (Russia)

ATC Code

B02BC30 (Local hemostatics in combinations)

Dosage Forms

Bottle OTC Icon Gelplastan Powder for topical application: 2.5 g bottle, 10 pcs.
Powder for topical application: 5 g bottle, 10 pcs.

Dosage Form, Packaging, and Composition

Powder for topical application 1 bottle
Gelatin 2.5 mg
Kanamycin (as monosulfate) 75 mg
Dry bovine blood plasma 175 mg

2.5 g – bottles (10) – cardboard packs.

Clinical-Pharmacological Group

Hemostatic agent for topical application

Pharmacotherapeutic Group

Topical hemostatic agent

Pharmacological Action

Gelplastan is an absorbable hemostatic agent for topical application.

The drug accelerates the process of thrombus formation at the site of application, has antibacterial activity, and is absorbed in body tissues.

Indications

  • To achieve hemostasis and tissue “gluing”, especially in extensive injuries of parenchymal organs (e.g., liver, spleen, kidneys);
  • In open musculoskeletal injuries.

ICD codes

ICD-10 code Indication
S36.0 Injury of spleen
S36.1 Injury of liver or gallbladder
S37.0 Injury of kidney
T14.1 Open wound of unspecified body region
T81.0 Haemorrhage and haematoma complicating a procedure, not elsewhere classified
ICD-11 code Indication
NB91.0Z Injury of spleen, unspecified
NB91.1Z Injury of liver, unspecified
NB92.0Z Injury of kidney, unspecified
ND56.1 Open wound of unspecified body region
NE81.0Z Hemorrhage or hematoma of other or unspecified sites complicating a procedure, not elsewhere classified

Dosage Regimen

The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen.

Gelplastan is applied topically.

The bottle with the drug is opened immediately before use. Immediately after drying the bleeding wound surface, the powder is applied in an even layer and pressed with a gauze pad until the bleeding stops completely.

If the layer of powder on the surface is insufficient, uncoagulated blood may appear. In this case, lift the gauze pad and add an additional amount of the drug from the bottle to the bleeding areas, then press again.

After the final stop of bleeding, the excess drug is removed. The dose of the drug depends on the intensity of bleeding and the area of the wound surface.

The maximum consumption of the drug per patient usually does not exceed 15 g, but it can also be used in a larger dose.

Adverse Reactions

Allergic reactions.

Contraindications

  • Children under 18 years of age;
  • Congenital and acquired disorders of the blood coagulation system;
  • Hypersensitivity to the components of the drug.

Pediatric Use

Contraindicated in children under 18 years of age.

Special Precautions

Gelplastan is supplied in sterile bottles.

Use only undamaged packaging. Re-sterilization is not possible.

During the production of the drug, raw materials from animals that are free from diseases of bacterial, mycoplasmal, prion, and viral etiology pathogenic to humans are used.

Drugs that reduce blood clotting should not be used simultaneously with Gelplastan.

Overdose

No reports of overdose cases are available.

Since the content of active components is very low, cases of overdose with Gelplastan are virtually impossible.

Drug Interactions

No interactions with other medicinal products have been established.

Storage Conditions

In a dry place, protected from light, at a temperature not exceeding 25°C (77°F).

Keep out of reach of children.

Shelf Life

Shelf life – 3 years.

Dispensing Status

Over-the-counter.

Important Safety Information

This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.

Medical Disclaimer

TABLE OF CONTENTS